Other Information
−Removed: During the three months ended September 30, 2025, the following adopted a “ Rule 10b5-1 trading arrangement ” (as defined in Item 408(a) of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading:
+Added: During the three months ended March 31, 2026, the following adopted a “ Rule 10b5-1 trading arrangement ” (as defined in Item 408(a) of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading:
Date Adopted (1)
1 unchanged sentence
Expiration Date (2)
−Removed: Walid Abi-Saab , Chief Medical Officer
−Removed: September 26, 2025
−Removed: December 31, 2026
−Removed: Robert Gut , Non-executive Director
+Added: Madhavan Balachandran , Non-executive Director
+Added: March 10, 2026
December 31, 2026
1 unchanged sentence
The first trade pursuant to this Rule 10b5-1 trading arrangement will be, in accordance with applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement, to the extent triggered under its terms.
−Removed: (2) The Rule 10b5-1 trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table.
−Removed: Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K, during the three months ended September 30, 2025.
+Added: (2) The Rule 10b5-1 trading arrangement is scheduled to expire on the date listed in the table, subject to earlier termination upon the sale of all shares subject to the Rule 10b5-1 trading arrangement, or as otherwise provided in the Rule 10b5-1 trading arrangement.
+Added: Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “ non-Rule 10b5-1 trading arrangement ,” in each case as defined in Item 408 of Regulation S-K, during the three months ended March 31, 2026.
See the Exhibit Index immediately preceding the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
−Removed: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K (File No.
−Removed: 001-36294) filed with the SEC on September 29, 2025).
−Removed: Amendment No.
−Removed: 3 to Third Amended and Restated Loan and Security Agreement, dated of September 22, 2025, by and among uniQure biopharma, B.V., uniQure, Inc., uniQure IP B.V., the Company and Hercules Capital, Inc.
−Removed: (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No.
−Removed: 001-36294) filed with the SEC on September 24, 2025).
+Added: Termination and Amendment Agreement, dated April 15, 2026, by and between uniQure biopharma B.V.
+Added: and CSL Behring LLC.
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
−Removed: The following financial information from our Quarterly Report on Form 10-Q for the period ended September 30, 2025, filed with the Securities and Exchange Commission on November 10, 2025, is formatted in Inline Extensible Business Reporting Language (“iXBRL”):
+Added: The following financial information from our Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, is formatted in Inline Extensible Business Reporting Language (“iXBRL”):
(i) Consolidated Balance Sheets;
3 unchanged sentences
and (v) Notes to Consolidated Financial Statements (tagged as blocks of text).
−Removed: The cover page from our Quarterly Report on Form 10-Q for the period ended September 30, 2025, filed with the Securities and Exchange Commission on November 10, 2025, is formatted in Inline Extensible Business Reporting Language (“iXBRL”).
+Added: The cover page from our Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, is formatted in Inline Extensible Business Reporting Language (“iXBRL”).
* Filed herewith.
10 unchanged sentences
(Principal Financial and Accounting Officer)
−Removed: November 10, 2025
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.